Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, Cirulli J, Goncalves J, Lebwohl M; KOMFORT Trial Investigators. Kim BS, et al. Among authors: lebwohl m. N Engl J Med. 2023 Feb 9;388(6):511-517. doi: 10.1056/NEJMoa2210699. N Engl J Med. 2023. PMID: 36780675 Clinical Trial.
Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.
Guttman-Yassky E, Facheris P, Da Rosa JC, Rothenberg-Lausell C, Del Duca E, David E, Estrada Y, Liu Y, Bose S, Chowdhury M, Munera C, Goncalves J, Nograles K, Kim BS, Lebwohl M. Guttman-Yassky E, et al. Among authors: lebwohl m. J Allergy Clin Immunol. 2023 Oct;152(4):916-926. doi: 10.1016/j.jaci.2023.06.023. Epub 2023 Jul 13. J Allergy Clin Immunol. 2023. PMID: 37453614 Free article.
Bexarotene use in refractory Darier's disease.
Guenin S, Lebwohl M. Guenin S, et al. Among authors: lebwohl m. Int J Dermatol. 2023 Nov;62(11):e587-e589. doi: 10.1111/ijd.16763. Epub 2023 Jun 29. Int J Dermatol. 2023. PMID: 37381738 No abstract available.
Spesolimab use in treatment of pyoderma gangrenosum.
Guénin SH, Khattri S, Lebwohl MG. Guénin SH, et al. JAAD Case Rep. 2023 Feb 4;34:18-22. doi: 10.1016/j.jdcr.2023.01.022. eCollection 2023 Apr. JAAD Case Rep. 2023. PMID: 36936866 Free PMC article. No abstract available.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Morita A, et al. Among authors: lebwohl mg. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. Lancet. 2023. PMID: 37738999 Clinical Trial.
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Navarini AA, Tang M, Thoma C, Duffin KC. Burden AD, et al. Among authors: lebwohl mg. Br J Dermatol. 2023 Jul 7;189(1):138-140. doi: 10.1093/bjd/ljad071. Br J Dermatol. 2023. PMID: 37075220 Free article. No abstract available.
719 results